Page 50 - 《中国药房》2026年4期
P. 50

·药物与临床·


          乌灵胶囊联合氟西汀治疗青少年首发中重度抑郁伴失眠的疗效

          与安全性分析
                                Δ

                                   1
                                            2
                                                    1 #
                 1*
          何 恋 ,舒燕萍 ,恽 渊 ,莫 芸 ,张 乾 (1. 贵州省第二人民医院药剂科临床药学室,贵阳 550004;
                           2
          2.贵州省第二人民医院普通精神科,贵阳 550004)
          中图分类号  R971;R969.4      文献标志码  A      文章编号  1001-0408(2026)04-0456-06
          DOI  10.6039/j.issn.1001-0408.2026.04.08


          摘   要  目的  探讨乌灵胶囊联合氟西汀治疗青少年首发中重度抑郁伴失眠的疗效与安全性。方法  回顾性收集2022年6月至
          2025年5月本院收治的476例首发中重度抑郁伴失眠青少年患者的临床资料,根据初始治疗方案的不同分为对照组(241例,单用
          氟西汀治疗)和观察组(235例,乌灵胶囊联合氟西汀治疗)。比较两组患者治疗前及治疗第4、8周的抑郁程度(汉密尔顿抑郁量表
          17项、抑郁自评量表评分),睡眠质量(匹兹堡睡眠质量指数评分、入睡潜伏期、夜间觉醒次数、总睡眠时间、睡眠效率),血清神经
          内分泌指标(皮质醇)和炎症指标(C反应蛋白、白细胞介素6),治疗第8周的有效率,以及不良反应发生情况。结果  治疗前,两组
          患者的抑郁程度、睡眠质量、血清神经内分泌和炎症指标比较,差异均无统计学意义(P>0.05);治疗第4、8周,两组患者上述指标
          均较同组治疗前显著改善,且观察组上述指标的改善均显著优于同期对照组(P<0.05);治疗第 8 周,观察组患者的有效率为
          90.21%,显著高于对照组的80.50%(P<0.05);两组患者恶心、头痛、乏力、口干、心悸的发生率及总不良反应发生率比较,差异均
          无统计学意义(P>0.05)。结论  乌灵胶囊联合氟西汀能够显著提高首发中重度抑郁伴失眠青少年患者的有效率,加速缓解抑郁
          症状,改善睡眠质量,并降低血清神经内分泌和炎症指标水平,且安全性良好。
          关键词  乌灵胶囊;氟西汀;中重度抑郁;失眠;青少年

          Efficacy  and  safety  analysis  of  Wuling  capsules  combined  with  fluoxetine  in  the  treatment  of  adolescents
          with first-episode moderate-to-severe depressive disorder accompanied by insomnia
                  1
                                                                    1
                                2
                                                      2
          HE Lian ,SHU Yanping ,YUN Yuan ,MO Yun ,ZHANG Qian(1.  Dept.  of  Clinical  Pharmacy,  the  Second
                                            1
          People’s  Hospital  of  Guizhou  Province,  Guiyang  550004,  China;2.  Dept.  of  General  Psychiatry,  the  Second
          People’s Hospital of Guizhou Province, Guiyang 550004, China)
          ABSTRACT    OBJECTIVE To investigate the efficacy and safety of Wuling capsules combined with fluoxetine in the treatment of
          adolescents  with  first-episode  moderate-to-severe  depressive  disorder  accompanied  by  insomnia.  METHODS  The  clinical  data  of
          476 adolescents with first-episode moderate-to-severe depression accompanied by insomnia admitted to our hospital from June 2022
          to May 2025, were retrospectively collected. According to the initial treatment regimen, patients were divided into a control group
         (241  cases,  treated  with  fluoxetine  alone)  and  an  observation  group (235  cases,  treated  with  Wuling  capsules  combined  with
          fluoxetine).  The  depression  severity (Hamilton  Depression  Rating  Scale-17  Item  and  the  Self-Rating  Depression  Scale  scores),
          sleep  quality (Pittsburgh  Sleep  Quality  Index  score,  sleep  latency,  wake  after  sleep  onset,  total  sleep  time,  sleep  efficiency),
          serum neuroendocrine indicator (cortisol) and inflammatory markers (C-reactive protein, interleukin-6) were compared between the
          two  groups  before  treatment  and  at  4th  and  8th  weeks  of  treatment. The  effective  rate  at  8th  weeks  and  the  occurrence  of  adverse
          drug  reactions (ADRs)  were  also  compared  between  the  two  groups.  RESULTS  Before  treatment,  there  were  no  significant
          differences  in  depression  severity,  sleep  quality,  serum  neuroendocrine  indicator,  and  inflammatory  markers  between  the  two
          groups (P>0.05). At 4th and 8th weeks, both groups showed significant improvement in these indicators compared to those before
                                                              treatment,   with   the   observation   group   demonstrating
              Δ 基金项目 国家自然科学基金项目(No.82460282);贵州省卫生
          健康委科学技术基金项目(No.gzwkj2025-534)                       significantly  greater  improvement  than  the  control  group  at  the
             *第一作者 主管药师,硕士。研究方向:临床药学。E-mail:                  corresponding  time  points  (P<0.05).  At  8th  week,  the
          694992071@qq.com
                                                              effective  rate  of  the  observation  group  was  90.21%,
              # 通信作者 副主任药师。研究方向:临床药学、医院药学。E-
          mail:zh84qian@163.com                               significantly  higher  than  80.50%  in  the  control  group (P<


          · 456 ·    China Pharmacy  2026 Vol. 37  No. 4                               中国药房  2026年第37卷第4期
   45   46   47   48   49   50   51   52   53   54   55